Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by SkywalkerofLukeon Jan 23, 2023 5:07pm

174 Views

Post# 35240823

Recent News

With the recent attention on AGN.c AGNPF’s Phase 1 DMT Clinical Stroke Study thought it’d be worth noting the recent developments from their Ifenprodil for chronic cough.

Earlier this month they announced a 180 patient, 90-day Phase 2b clinical study of Ifenprodil for chronic cough will begin in Q3.

Keeping my eye out for any news with the chronic cough market expected to reach $11.38B by 2029 and AGN planning to file an investigational new drug application with the FDA shortly.

https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/171/algernon-pharmaceuticals-announces-plans-for-a-180-patient

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario